UBS Group
CAI

UBS Group’s Caris Life Sciences CAI Stock Holding History

UBS Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.4M Sell
1,423,371
-1,322,440
-48% -$23.7M ﹤0.01% 2437
2026
Q1 		$49.1M Buy
2,745,811
+561,831
+26% +$12.3M 0.01% 1665
2025
Q4 		$58.9M Buy
2,183,980
+1,948,107
+826% +$54.9M 0.01% 1458
2025
Q3 		$7.14M Buy
+235,873
New +$7.52M ﹤0.01% 3662

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's CAI Position: Q2 2026 in Review

UBS Group reduced its Caris Life Sciences (CAI) stake by 48% in Q2 2026, selling an estimated $23.7M and leaving 1,423,371 shares worth $25.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2437.

UBS Group first reported a position in CAI in Q3 2025 and has held it in 4 quarters since. The position peaked at $58.9M in Q4 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • UBS Group held 1,423,371 shares of Caris Life Sciences worth $25.4M as of Q2 2026.
  • UBS Group sold 1,322,440 Caris Life Sciences shares in Q2 2026, an estimated $23.7M.
  • Caris Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2437 holding.
  • UBS Group first reported a position in Caris Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • UBS Group's Caris Life Sciences position peaked at $58.9M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.